More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Hyperforin . DCHA [238074-03-8]
Chemical Structure
Chemical Structure
Chemical Structure

Hyperforin . DCHA [238074-03-8]

Research Use Only
AG-CN2-0008
AdipoGen Life Sciences
CAS Number238074-03-8
DownloadMSDS
Product group Chemicals
Estimated Purity>97%
Molecular Weight535.8 . 182.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Hyperforin . DCHA [238074-03-8]
  • Delivery Days Customer
    10
  • CAS Number
    238074-03-8
  • Certification
    Research Use Only
  • Estimated Purity
    >97%
  • Hazard Information
    Warning
  • Molecular Formula
    C35H51O4 . C12H24N
  • Molecular Weight
    535.8 . 182.3
  • Scientific Description
    Chemical. CAS: 238074-03-8. Formula: C35H51O4 . C12H24N. MW: 535.8 . 182.3. Isolated from St. Johns wort (Hypericum perforatum). Key constituent of St. Johns wort. Shows properties of potential pharmacological interest, including antibacterial, anti-malarial, anti-inflammatory, anti-cancer and anti-angiogenic effects. Anti-depressant and anxiolytic compound. Specific activator of TRPC6 channels. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate). Activator of the pregnane X receptor (PXR). Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism. Potential anti-Alzheimer compound. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor. - Key constituent of St. Johns wort. Shows properties of potential pharmacological interest, including antibacterial [1], anti-malarial [13], anti-inflammatory [7, 14], anti-cancer and anti-angiogenic effects [5, 10]. Anti-depressant and anxiolytic compound [3]. Specific activator of TRPC6 channels [11]. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate) [4]. Activator of the pregnane X receptor (PXR) [2]. Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism [8]. Potential anti-Alzheimer compound [6, 9, 15]. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor [12]. Based on the anti-inflammatory activity of Hyperforin and its simultaneous blockade of multiple signaling pathways, such as IFN-gamma/IL-1beta/TNF-alpha, JAK/STAT, NF-kappaB and MAPK it has been suggested a valuable agent for cytokine storm treatment during COVID-19 [16].
  • SMILES
    C1CCC(CC1)NC1CCCCC1.CC(C)C(=O)[C@@]12C(O)=C(CC=C(C)C)C(=O)[C@@](CC=C(C)C)(C[C@H](CC=C(C)C)[C@@]1(C)CCC=C(C)C)C2=O
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria: C.M. Schempp, et al.; Lancet 353, 2129 (1999)
  • St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor: L.B. Moore, et al.; PNAS 97, 7500 (2000)
  • Hyperforin-antidepressant activity by a novel mechanism of action: W.E. Müller, et al.; Pharmacopsychiatry 34 (Suppl 1), S98 (2001)
  • Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology: P.J. Nathan; J. Psychopharmacol. 15, 47 (2001) (Review)
  • Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis: C.M. Schempp, et al.; Oncogene 21, 1242 (2002)
  • Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort: M.L. Buchholzer, et al.; J. Pharmacol. Exp. Ther. 301, 714 (2002)
  • Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase: D. Albert, et al.; Biochem. Pharmacol. 64, 1767 (2002)
  • Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures: B.J. Komoroski; Drug Metab. Dispos. 32, 512 (2004)
  • NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort: V. Kumar, et al.; J. Pharmacol. Sci. 102, 47 (2006)
  • Hyperforin, a new lead compound against the progression of cancer and leukemia? C. Quiney, et al.; Leukemia 20, 1519 (2006)